Document text
Principal Investigator: SUMIT K CHANDA
Organization: SCRIPPS RESEARCH INSTITUTE, THE
Fiscal Year: 2022
Award: $67,624,156
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY
The ongoing COVID-19 pandemic has brought to light an urgent need to enhance the therapeutic preparedness
for future viral outbreaks and pandemics. The overarching goal of the “Center for Antiviral Medicines &
Pandemic Preparedness” (CAMPP) is thus to develop novel strategies and enhance the drug discovery
pipelines for direct-acting antivirals against RNA viruses of pandemic concern. The specific focus of CAMPP will
be to develop antivirals against coronaviruses SARS-CoV-2 (SCV2), SARS and MERS; flaviviruses including
Zika, West Nile and Dengue virus; and hemorrhagic fever viruses including the filovirus Ebola, and bunyaviruses
Severe fever with thrombocytopenia syndrome virus and Lassa virus. Infection by any of these agents has the
potential to cause severe human disease with significant mortality rates and current options for antiviral
treatments are limited. The antiviral drug remdesivir and several monoclonal antibody treatments have received
emergency use authorization (EUA) for treatment of COVID-19, and the polymerase inhibitor molnupiravir by
Merck is expected to be granted EUA in the near future. Monoclonal antibodies are also available to treat Ebola
virus infection, however, none of these drugs can be administered orally, posing additional challenges in treating
early infection. There are no approved treatments for the CAMPP flaviviruses and hemorrhagic fever viruses.
Toward this end, we have assembled a world class multidisciplinary team of investigators with expertise in
virology of relevant viruses, structural and computational biology, chemoproteomics, pharmacology and
organoid/animal models, who will work closely with the drug development experts at the drug discovery division
of The Scripps Research Institute, Calibr, to further the development of four major classes of promising assets
in our drug discovery pipeline. First, we propose to develop a potentially best-in-class, orally bioavailable
coronavirus protease (CLpro) inhibitor for coronaviruses including SCV2, from a late-stage drug asset undergoing
ADME optimization that is expected to enter IND-enabling studies within the next three years. Second, we will
identify and optimize RNA polymerase inhibitors for SCV2 and other CAMPP viruses, with the goal of reaching
IND-enabling studies within the next four years. The third focus of our proposal is to develop antivirals against
other ‘druggable’ proteins encoded by SCV2 and additional viruses posing a pandemic threat; these assets
include inhibitors of SCV2 helicase, E-protein encoded ion channel activity, entry and fusion activities, and
nucleocapsid, with the goal of obtaining in vivo proof-of-concept for a subset of these mid-stage assets. Finally,
we propose to target traditionally considered ‘undruggable’ non-enzymatic proteins including SCV2 and flaviviral
structural proteins as well as RNA structure, to develop novel strategies for antiviral drug development. CAMPP
provides a highly integrated infrastructure of investigators, expertise and external pharmaceutical and founding
partners that will ensure the Center’s success in achieving our goals and navigating challenges of the drug
discovery process.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Animal Model><Animal Models and Related Studies><Antibody Therapy><Antiproteases><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Architecture><Back><Bioavailability><Biologic Availability><Biologic Products><Biological Agent><Biological Availability><Biological Products><Breakbone Fever Virus><Bunyavirus><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 virus><Capsid><Chemicals><Chemistry><Clinical><Clinical Evaluation><Clinical Testing><Clinical Treatment Moab><Clinical Trials><CoV-2><CoV2><Computational Biology><Coronaviridae><Coronavirus><DNA Helicases><DNA Unwinding Proteins><DNA unwinding enzyme><Dengue Virus><Dengue fever virus><Development><Disease Outbreaks><Dorsum><Dose><Drug Targeting><Drugs><EBOV><Ebola><Ebola virus><Ebola-like Viruses><Egypt 101 virus><Endopeptidase Inhibitors><Engineering / Architecture><Ensure><Equilibrium><Esteroproteases><FDA EUA><FDA Emergency Use Authorization><Filoviridae><Filovirus><Flavivirus><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Foundations><Funding><Future><GS-5734><Gene Transcription><Genetic Transcription><Goals><Grant><Group B Arbovirus><Health><Human><Human Resources><Individual><Industry><Infection><Infrastructure><Intention><Interdisciplinary Research><Interdisciplinary Study><Investigators><Ion Channel><Ionic Channels><Lassa fever virus><Lassa virus><MERS><MERS coronavirus disease><MERS-CoV disease><Manpower><Mediating><Medication><Medicine><Membrane Channels><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Modern Man><Monoclonal Antibodies><Multidisciplinary Collaboration><Multidisciplinary Research><Non-Polyadenylated RNA><Nucleocapsid><Nucleosides><Oral><Organoids><Orthobunyavirus><Outbreaks><Outcome><Peptidase Inhibitors><Peptidases><Peptide Hydrolase Inhibitors><Peptide Hydrolases><Peptide Peptidohydrolase Inhibitors><Pharmaceutic Preparations><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacology><Physiologic Availability><Polymerase><Position><Positioning Attribute><Preparedness><Process><Protease Antagonists><Protease Gene><Protease Inhibitor><Proteases><Proteinase Inhibitors><Proteinases><Proteins><Proteolytic Enzymes><RNA><RNA Expression><RNA Gene Products><RNA Polymerase Inhibitor><RNA Synthesis Inhibitors><RNA Viruses><RNA chemical synthesis><RNA synthesis><Readiness><Research Institute><Research Personnel><Researchers><Ribonucleic Acid><Ritonavir><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CO-V2><SARS-COVID-2><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe Fever with Thrombocytopenia Syndrome Virus><Severe Fever with Thrombocytopenia virus><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Structural Protein><Structure><Technology><Testing><Therapeutic><Transcription><Veklury><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Virus Diseases><WNV><West Nile><West Nile virus><Work><Wuhan coronavirus><ZIKA><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy><anti-viral therapy development><anti-virals><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antiviral compound><antiviral development><antiviral drug development><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><balance><balance function><base><biologics><biopharmaceutical><biopharmaceutical company><biopharmaceutical industry><biotherapeutic agent><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><chemical library><chemoproteomics><clinical development><clinical test><computer biology><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><drug candidate><drug development><drug discovery><drug/agent><ebolavirus><emergency use authorization><flexibility><flexible><hCoV19><helicase><hemorrhagic fever virus><high risk><human disease><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibitor><innovate><innovation><innovative><interdisciplinary approach><lead optimization><mAbs><model of animal><model organism><molnupiravir><mortality><multidisciplinary><multidisciplinary approach><nCoV2><new approaches><next generation><norvir><novel><novel approaches><novel strategies><novel strategy><nucleoside inhibitor><pandemic><pandemic disease><pandemic preparedness><personnel><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><remdesivir><research clinical testing><screening><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><small molecule libraries><structural biology><success><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment center><viral infection><viral infectious disease treatment><virology><virus infection><virus protein><virus-induced disease>